Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Short term Debt (2016 - 2024)

Historic Short term Debt for Cytosorbents (CTSO) over the last 7 years, with Q1 2024 value amounting to $2.5 million.

  • Cytosorbents' Short term Debt changed N/A to $2.5 million in Q1 2024 from the same period last year, while for Mar 2024 it was $2.5 million, marking a year-over-year change of. This contributed to the annual value of $2.5 million for FY2023, which is N/A changed from last year.
  • Per Cytosorbents' latest filing, its Short term Debt stood at $2.5 million for Q1 2024.
  • Over the past 5 years, Cytosorbents' Short term Debt peaked at $9.2 million during Q3 2020, and registered a low of $833333.0 during Q3 2023.
  • Its 3-year average for Short term Debt is $4.3 million, with a median of $3.3 million in 2020.
  • The largest annual percentage gain for Cytosorbents' Short term Debt in the last 5 years was 70000.04% (2020), contrasted with its biggest fall of 15000.0% (2020).
  • Quarter analysis of 3 years shows Cytosorbents' Short term Debt stood at $9.2 million in 2020, then tumbled by 72.73% to $2.5 million in 2023, then changed by 0.0% to $2.5 million in 2024.
  • Its last three reported values are $2.5 million in Q1 2024, $2.5 million for Q4 2023, and $833333.0 during Q3 2023.